Platelet-rich plasma for androgenic alopecia: A randomized, placebo-controlled, double-blind study and combined mice model experiment

J Cosmet Dermatol. 2021 Oct;20(10):3227-3235. doi: 10.1111/jocd.14089. Epub 2021 Apr 20.

Abstract

Background: Platelet rich plasma (PRP) has been accepted as a potential therapy for treating androgenetic alopecia (AGA).

Objective: To fully clarify the underling molecular mechanisms of PRP action on hair growth and promote its clinical applications.

Methods: In this study, we used mice models and protein biochip to explore the specific mechanisms of PRP regulating hair growth. Then, we performed a randomized, placebo-controlled, double-blind, half-head study of 52 AGA patients to verify the therapeutic efficacy of PRP in Chinese AGA patients.

Results: The results confirmed that PRP treatment boosted hair regrowth, accelerated hair cycling, and the effect sustained for more than one hair cycle in mice. Protein biochip evaluation confirmed remarkably upregulated β-Catenin, PDGF, and AKT signaling and repressed p53 signaling in PRP injection group. Clinically, mean hair count, density, diameter, and anagen hair ratio in PRP group showed a significant improvement at 6 month comparing to control side.

Conclusions: Overall, we elucidated the specific molecular mechanism of PRP action on hair growth and proved the therapeutic efficacy and safety of PRP in Chinese AGA patients.

Keywords: androgenetic alopecia; hair follicle; hair loss; platelet-rich plasma.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Alopecia* / therapy
  • Animals
  • Double-Blind Method
  • Hair
  • Humans
  • Mice
  • Platelet-Rich Plasma*
  • Signal Transduction
  • Treatment Outcome